Results 31 to 40 of about 22,516 (228)

Baseline characteristics of 39 CTC-positive CRPC patients.

, 2020
Baseline characteristics of 39 CTC-positive CRPC patients.
Toshiyuki China (8362743), Shuji Isotani (21065), Shigeo Horie (185545), Masayoshi Nagata (8362734), Zen-u Hotta (8362740), Yoshiro Sakamoto (8362752), Qi Hou (494583), Kosuke Kitamura (8362746), Satoru Muto (758040), Naoya Nagaya (8362731), Kazuhito Matsushita (8362749), Yan Lu (32611), Mayuko Kanayama (8362737)   +12 more
core   +1 more source

Baseline characteristics of all CRPC patients in treatment-failure cohort.

, 2020
Baseline characteristics of all CRPC patients in treatment-failure cohort.
Toshiyuki China (8362743), Shuji Isotani (21065), Shigeo Horie (185545), Masayoshi Nagata (8362734), Zen-u Hotta (8362740), Yoshiro Sakamoto (8362752), Qi Hou (494583), Kosuke Kitamura (8362746), Satoru Muto (758040), Naoya Nagaya (8362731), Kazuhito Matsushita (8362749), Yan Lu (32611), Mayuko Kanayama (8362737)   +12 more
core   +1 more source

LPCAT1 enhances castration resistant prostate cancer progression via increased mRNA synthesis and PAF production.

PLoS ONE, 2020
Our previously study shown that Lysophosphatidylcholine Acyltransferase1 (LPCAT1) is overexpressed in castration resistant prostate cancer (CRPC) relative to primary prostate cancer (PCa), and androgen controls its expression via the Wnt signaling ...
Chao Han, Guopeng Yu, Yuanshen Mao, Shangqing Song, Long Li, Lin Zhou, Zhong Wang, Yushan Liu, Minglun Li, Bin Xu   +9 more
doaj   +1 more source

Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms.

, 2013
BACKGROUND: Median overall survival (OS) in men with metastatic castration-resistant prostate cancer (CRPC) was 13-16 mo in the predocetaxel era. Prognostic nomograms for survival estimation in CRPC were constructed prior to the introduction of docetaxel
Pezaro, Carmel, Omlin, Aurelius, Thompson, Emilda, Sandhu, Shahneen, Maier, Gal, de Bono, Johann, Attard, Gerhardt, Bianchini, Diletta, Olmos, David, Ferraldeschi, Roberta, Parker, Chris, Mukherji, Deborah, Mulick Cassidy, Amy   +12 more
core   +1 more source

Role of the Judiciary in Victim Compensation in India – With Special Reference to Data Collected from the State of Odisha, India

BRICS Law Journal
This study examines the legal and legislative framework for victim compensation in India, focusing on the Code of Criminal Procedure’s provisions and their interpretation by the courts, using data collected from lower courts in the state of Odisha.
E. Kanungo, P. Chattoraj
doaj   +1 more source

A drug comorbidity index to predict mortality in men with castration resistant prostate cancer.

PLoS ONE, 2021
BackgroundThe Charlson Comorbidity Index is a poor predictor of mortality in men with castration resistant prostate cancer (CRPC). To improve this prediction, we created a comorbidity index based on filled prescriptions intended to be used in registry ...
Giuseppe Fallara, Rolf Gedeborg, Anna Bill-Axelson, Hans Garmo, Pär Stattin   +4 more
doaj   +1 more source

Regression of Castration-Resistant Prostate Cancer by a Novel Compound HG122

Frontiers in Oncology, 2021
Prostate cancer (PCa) is a common aggressive disease worldwide which usually progresses into incurable castration-resistant prostate cancer (CRPC) in most cases after 18–24 months treatment.
Xiaonan Cong, Yundong He, Haigang Wu, Dingxiang Wang, Yongrui Liu, Ting Shao, Mingyao Liu, Zhengfang Yi, Jianghua Zheng, Shihong Peng, Tao Ding, Tao Ding   +11 more
doaj   +1 more source

MSCs contribute to CRPC.

, 2013
This diagram represents a transformed prostate gland. Rounded turquoise rectangles indicate epithelial cells with an irregular nuclear shape and the larger pink half moon shapes represent the stromal compartment.
Veronica R. Placencio (361478), Xiaohong Li (71964), Gloria Fritz (361482), Neil A. Bhowmick (275957), Taylor P. Sherrill (361481)   +4 more
core   +1 more source

Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy.

PLoS ONE, 2020
PURPOSE:To determine whether SRD5A2 promoter methylation is associated with cancer progression during androgen deprivation therapy (ADT) in CRPC. PATIENTS AND METHODS:In a Local CRPC cohort, 42 prostatic specimens were collected from patients who were ...
Zongwei Wang, Tuo Deng, Xingbo Long, Xueming Lin, Shulin Wu, Hongbo Wang, Rongbin Ge, Zhenwei Zhang, Chin-Lee Wu, Mary-Ellen Taplin, Aria F Olumi   +10 more
doaj   +1 more source

Mesenchymal stem cells desensitize castration-resistant prostate cancer to docetaxel chemotherapy via inducing TGF-β1-mediated cell autophagy

Cell & Bioscience, 2021
Background Mesenchymal stem cells (MSCs) have been proved to drive castration resistant prostate cancer (CRPC). In this study, we aim to investigate the contribution of MSCs to the development of docetaxel resistance in CRPC cells and its potential ...
Yang Yu, Fu-han Yang, Wen-tao Zhang, Ya-dong Guo, Lin Ye, Xu-dong Yao   +5 more
doaj   +1 more source